AI-generated from publicly available materials.The U.S. Department of Health and Human Services (HHS) has launched the Surpass program, aiming to revolutionize clinical trials by addressing existing barriers and enhancing trial design and execution.
Announced on September 30, Surpass—standing for simulation-augmented, real-time platform adaptive seamless trials—will be implemented through the Advanced Research Projects Agency for Health (ARPA-H). While specific details remain sparse, the initiative will utilize predictive computational models, shared infrastructure, and real-time data analysis to facilitate quicker and more efficient decision-making in drug development. HHS Secretary Robert Kennedy Jr. emphasized the need to transition from fragmented clinical trials to a more cohesive system that promotes patient access and simplifies recruitment.
In addition to Surpass, ARPA-H is introducing three related projects, two in collaboration with the University of Texas at Austin Dell Medical School. The Stack project aims to leverage artificial intelligence to activate clinical sites and transform research-naïve locations into trial-capable sites. The Commons initiative will establish a national consent architecture to provide access to regulatory-grade data, while the Cinch program focuses on empowering cancer patients through improved care navigation.
These initiatives collectively aim to modernize the clinical trial landscape, reduce costs and delays, and enhance the U.S.'s position in biotechnology and drug development. Alicia Jackson, Ph.D., director of ARPA-H, highlighted the urgency of these efforts, noting that without effective clinical trials, advancements in treatment and cures risk being lost to other countries. The recent Operation Trial Blazer further underscores this commitment, seeking to expedite phase 1 trials and retain clinical research within the U.S.